SEARCH

SEARCH BY CITATION

References

  • Aldridge, W. N. & E. Reiner: Enzyme inhibitors as substrates, interaction of esterases with esters of organophosphorus and carbamic acids. In: Frontiers of biology 26. North-Holland, Amsterdam, 1972.
  • Badavi, A. F. M. & A. H. B. Hasan: Carbamates as chemical warfare agent: history review of toxicities and structures. ASA Newslett. 1995, 95, 1011.
  • Bevandić, Z., A. Deljac, M. Maksimović, B. Bošković & Z. Binenfeld: Methylthio analogues of PAM-2, TMB-4 and Obidoxime as antidotes in organophosphate poisonings. Acta Pharm. Jugosl. 1985, 35, 213218.
  • Binenfeld, Z., M. Maksimović & V. Deljac: New in vitro method for screening antisoman activity. Acta Pharm. Jugoslav. 1982, 32, 145147.
  • De Jong, L. P. A., M. A. A. Verhagen, J. P. Langeberg, I. Hagedorn & M. Loffler: The bispyridinium-dioxime Hlo-7. A potent reactivator for acetylcholinesterase inhibited by stereoisomers of tabine and somau. Biochem. Pharmacol. 1989, 38, 633640.
  • Ellman, G. L., K. D. Courtney, V. Andres, Jr. & R. M. Featherstone: A new and rapid colorimetric detremination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 8895.
  • Fusek, J., J. Bajgar & J. Patocka: The biological effects of highly toxic carbamates. ASA Newslett. 1996, 96, 1314.
  • Galoši, A., A. Deljac, V. Deljac & Z. Binenfeld: Reactivators of acetylcholinesterase inhibited by organophosphorus compounds. Imidazole derivatives. Acta Pharm. Jugosl. 1988, 38, 2329.
  • Gray, A. P.: Design and structure-activity relationships of antidotes to organophosphorus anticholinesterase agents. Drug Metab. Rev. 1984, 15, 557589.
  • Kassa, J. & J. Bielavsky: The efficacy of monopyridinium (2-PAAM, 2-PAEM) and bispyridinium (obidoxime, HI-6) oximes against mevinphos in mice. Pharmacology & Toxicology 1997, 81, 144146.
  • Lovrić, J., V. Krenajz-Sirotković & N. Burger: Acute toxicity three novel derivatives of pyridinium chloride to bacteria, human cell culture and rodents. Period. Biol. 2001, 103, E. 347350.
  • Lucić, A., B. Radić, M. Peraica, M. Mesić, I. Primožić & Z. Binenfeld: Antidotal efficacy of quinuclidinium oximes against soman poisoning. Arch. Toxicol. 1997, 71, 467470.
  • Maksimović, M., B. Bošković, Lj. Radović, V. Tadić, V. Deljac & Z. Binenfeld: Antidotal effects of bis-pyridinium-2-monooxime carbonyl derivatives in intoxications with highly toxic organophosphorus compounds. Acta Pharm. Jugoslav. 1980, 30, 151160.
  • Radić, B., A. Lucić, M. Peraica & V. Bradamante: Treatment of carbamate and organophosphate intoxication with new oximes. Acta Pharm. 1999, 51, 7177.
  • Radić, B., A. Lucić, M. Peraica, A.-M. Domijan & V. Bradamante: Efficiency of imidazolium and quinuclidinium derivatives combined with HI-6 or diazepam in soman and tabun poisoning. Acta Pharm. 2001, 51, 19.
  • Reiner, E.: Inhibition of acetylcholinesterase by 4,4′-bipiridine and its effect upon phosphylation of the enzyme. Croat. Chem. Acta 1986, 59, 925931.
  • Reiner, E., M. Škrinjarić-Špoljar & V. Simeon-Rudolf: Binding sites on acetylcholinesterase and buthyrylcholinesterase for pyridiniun and imidazolium oximes, and other reversible ligands. Period. Biol. 1996, 98, 325329.
  • Shih, T. M.: Comparison of several oximes on reactivation of soman-inhibited blood, brain and tissue cholinesterase activity in rats. Arch. Toxicol. 1993, 67, 637646.
  • Srivatsan, M.: Effects of organophosphates on cholinesterase activity and neurite regeneration in Aplysia. Chem. Biol. Interact. 1999, 119–120, 371378.
  • Škrinjarić-Špoljar, M., N. Burgner & J. Lovrić: Inhibition of acetylcholinesterase by three new pyridinium compounds and their effect on phosphonylation of the enzyme. J. Enz. Inhib. 1999, 14, 331341.
  • Thompson, W. R.: Use of moving averages and interpolation to estimate median-effective dose. Bacteriol. Rev. 1947, 11, 115145.
  • Van Helden, H. P. M., R. W. Busker, B. P. C. Melchers & P. L. B. Bruijnzeel: Pharmacological effects of oximes: how relevant are they? Arch. Toxicol. 1996, 70, 779786.
  • Weil, C. S.: Tables for convenient calculation of median-effective dose (LD50 or ED50) and instruction in their use. Biometrics 1952, 8, 249263.